ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · HP_0001250

Seizure

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Seizure. Diseases, record HP_0001250. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001250

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Seizure
Open Targets ID
HP_0001250
Other names
Epileptic seizure, Seizures
Highest stage of its drugs
Approval, for 34 of its 81 drugs, from DailyMed, FDA, PMDA and TTD

Source Open Targets

Drugs81

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
LEVETIRACETAMCHEMBL1286Small moleculeApprovalDailyMed and PMDA1502121Drugs and targets
CANNABIDIOLCHEMBL190461Small moleculeApprovalDailyMed986Drugs and targets
PERAMPANELCHEMBL1214124Small moleculeApprovalDailyMed877Drugs and targets
TOPIRAMATECHEMBL220492Small moleculeApprovalDailyMed and PMDA855Drugs and targets
GANAXOLONECHEMBL1568698Small moleculeApprovalFDA and TTD755Drugs and targets
PHENYTOINCHEMBL16Small moleculeApprovalDailyMed2044Drugs and targets
LACOSAMIDECHEMBL58323Small moleculeApprovalDailyMed and PMDA1044Drugs and targets
BRIVARACETAMCHEMBL607400Small moleculeApprovalDailyMed and PMDA644Drugs and targets
VALPROIC ACIDCHEMBL109Small moleculeApprovalDailyMed644Drugs and targets
CARBAMAZEPINECHEMBL108Small moleculeApprovalDailyMed1533Drugs and targets

1 to 10 of 81

See all 81 drugs

Targets157

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
SCN8ASodium channel alpha subunit13Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor; Sodium channel protein type VIII alpha subunit inhibitorApprovalhttps://conductscience.org/library/genes/6334Drugs and targets
GABRA1GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2554Drugs and targets
GABRA2GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2555Drugs and targets
GABRA3GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2556Drugs and targets
GABRA4GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2557Drugs and targets
GABRA5GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2558Drugs and targets
GABRA6GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2559Drugs and targets
GABRB1GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2560Drugs and targets
GABRB2GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2561Drugs and targets
GABRB3GABA-A receptor; anion channel12GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2562Drugs and targets

1 to 10 of 157

See all 157 targets

Trials102

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01618695A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset SeizuresPhase 39402020-06-05Partial-onset SeizuresPERAMPANELOpen Targets' reading of its recordClinicalTrials.gov
NCT00235755Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in EpilepsyPhase 35392011-11-07SeizuresEZOGABINEIts record names the diseaseClinicalTrials.gov
NCT03355209A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut SyndromePhase 32962025-07-03Lennox Gastaut SyndromeFENFLURAMINEIts record names the diseaseClinicalTrials.gov
NCT01720667Efficacy of Intravenous Levetiracetam in Neonatal SeizuresPhase 1/22802019-08-21Neonatal SeizuresLEVETIRACETAM, PHENOBARBITALIts record names the diseaseClinicalTrials.gov
NCT02544763A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Phase 32242020-09-23Tuberous Sclerosis Complex, SeizuresCANNABIDIOLIts record names the diseaseClinicalTrials.gov
NCT00175825A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.Phase 22102018-08-22EpilepsyBRIVARACETAMIts record names the diseaseClinicalTrials.gov
NCT02544750An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Phase 31992022-07-14Tuberous Sclerosis Complex, SeizuresCANNABIDIOLIts record names the diseaseClinicalTrials.gov
NCT02072824A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.Phase 31752018-10-09Partial Onset SeizuresPREGABALINOpen Targets' reading of its recordClinicalTrials.gov
NCT02721069Repeat Dose Safety Study of NRL-1 in Epilepsy SubjectsPhase 31752022-01-31Acute Repetitive Seizures, Breakthrough SeizuresDIAZEPAMOpen Targets' reading of its recordClinicalTrials.gov
NCT03478982Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure PatternPhase 21562021-02-03EpilepsyALPRAZOLAMIts record names the diseaseClinicalTrials.gov

1 to 10 of 102

See all 102 trials

Comparisons in its trials35

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
GWP42003-P (Double-blind Phase) vs Placebo (Double-blind Phase): deaths from any cause0 of 751 of 124199NCT02544750Trial comparisons
GWP42003-P (Double-blind Phase) vs Placebo (Double-blind Phase): serious adverse events18 of 7538 of 124199NCT02544750Trial comparisons
Intravenous Phenobarbital vs Intravenous Levetiracetam: deaths from any cause1 of 422 of 64106NCT01720667Trial comparisons
Intravenous Phenobarbital vs Intravenous Levetiracetam: serious adverse events5 of 421 of 64106NCT01720667Trial comparisons
Ganaxolone vs Placebo: deaths from any cause0 of 500 of 51101NCT03572933Trial comparisons
Ganaxolone vs Placebo: serious adverse events6 of 505 of 51101NCT03572933Trial comparisons
Intravenous Levetiracetam vs Intravenous Phenobarbital: Number of Neonates With Seizure Termination at 1 Hour After Treatment26 of 5328 of 3083NCT01720667Trial comparisons
Intravenous Levetiracetam vs Intravenous Phenobarbital: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg)15 of 5324 of 3083NCT01720667Trial comparisons
Intravenous Levetiracetam vs Intravenous Phenobarbital: LEV Dose Escalation Component4 of 533 of 3083NCT01720667Trial comparisons
1 Week Levetiracetam vs 6 Week Levetiracetam: deaths from any cause2 of 400 of 4181NCT02334722Trial comparisons

1 to 10 of 35

See all 35 comparisons in its trials

Papers from its trials61

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
40365924RESULT1PubMed
39979559RESULT1PubMed
38450918RESULT1PubMed
38049197RESULT1PubMed
34957550RESULT2PubMed
31333569RESULT1PubMed
30679288RESULT1PubMed
30289769RESULT1PubMed
27265725RESULT1PubMed
22495532RESULT1PubMed

1 to 10 of 61

See all 61 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001250

GET https://conductscience.org/api/diseases/v1/HP_0001250/drugs?page=2

API referenceFor AI assistants